



Attorney's Docket No.: 12071-003001 / SP-21 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : John R. Neefe *et al.*

Serial No. : 09/891,823

Filed : June 26, 2001

Title : HUMAN PAPILLOMA VIRUS TREATMENT

Art Unit : 1648

Examiner : Ali R. Salimi

Commissioner for Patents  
Washington, D.C. 20231

#17  
Amended  
04.23.03  
RECEIVED

APR 18 2003

TECH CENTER 1600/2900

RESPONSE TO OFFICE ACTION

In response to the Office Action dated October 16, 2002, please amend the application as follows.

In the Claims:

Cancel claims 5, 7, and 14-35 without prejudice.

Amend claims 1, 2, and 4 as follows:

B1  
1. (Amended) A method of treating a wart in a subject, the method comprising administering, to a subject who has been identified as having a wart, a composition comprising a fusion protein comprising (1) an Hsp60 protein or an immunostimulatory fragment thereof, and (2) a human papilloma virus (HPV) E7 protein or an antigenic fragment thereof, wherein the composition is administered in an amount sufficient to treat the wart, wherein the wart is caused by an infection with a first type of HPV, and wherein the HPV E7 protein or antigenic fragment thereof is of a second type of HPV that differs from the first type of HPV.

2. (Amended) The method of claim 1, wherein the Hsp60 protein is a mycobacterial hsp.

04/16/2003 HGUETA1 00000098 09891823

01 FC:1202

378.00 OP

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

April 9, 2003

Date of Deposit

Signature

Annette Mejia

Annette Mejia

Typed or Printed Name of Person Signing Certificate